Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

There are many different exchange-traded fund (ETF) providers in the industry, but Vanguard stands out as one of the best. Its plethora of offerings, low cost, and interface make it a top choice for ...

Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Click ...

A daily pill that is cheaper and easier to take than currently available weight loss drugs helps people lose around a tenth ...

Apple became the first $1 trillion company on U.S. public markets in 2018. Six of the eight companies to follow in Apple’s ...

Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a ...

Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without ...

But these eye-popping innovations have an effect only if they can make their way to the patients who need them. That reality ...

The direct-to-consumer model is now being applied to the patient experience and broader healthcare system. New tools are reducing barriers and friction, offering greater choice and personalization and ...

With one in eight adults taking drugs like Ozempic and Mounjaro, emerging evidence shows that the medication has potential to ...

Eli Lilly and Company’s LLY stock crossed the $1000 per share mark for the first time on Nov. 12, reaching new highs. It is ...

Orforglipron, a GLP-1 drug taken as a pill, achieved positive results in people with obesity and type 2 diabetes, although it ...